Acetazolamide Tablets

This product is a carbonic anhydrase inhibitor, which can inhibit the production of aqueous humor and reduce intraocular pressure. The ease of aqueous humor outflow does not change. Acetazolamide can inhibit the activity of carbonic anhydrase in the ciliary epithelium, thereby reducing the production of aqueous humor (50% to 60%) and lowering intraocular pressure.

The main ingredients of this product and their chemical names: Main ingredient: Acetazolamide Chemical name: N-[5-(sulfamoyl)-1,3,4-thiadiazol-2-yl]acetamide. Molecular formula and molecular weight: C4H6N4O3S2, 222.25.

Suitable for treating various types of glaucoma

Common dosage for adults: 1. For open-angle glaucoma, take 250 mg (1 tablet) orally for the first time, 1-3 times a day. The maintenance dose should be determined according to the patient's response to the drug. Try to use a smaller dose to control intraocular pressure; generally, 250 mg (1 tablet) twice a day can keep intraocular pressure within the normal range. 2. For secondary glaucoma and preoperative intraocular pressure reduction, take 250 mg (1 tablet) orally, once every 4-8 hours, generally 2-3 times a day. (3) For acute cases, double the initial dose to 500 mg (2 tablets), and then use 125-250 mg (0.5-1 tablet) for maintenance, 2-3 times a day.

Common adverse reactions after medication include: 1. Numbness and tingling in the limbs; 2. General malaise syndrome: fatigue, weight loss, drowsiness, depression, lethargy, decreased libido, etc.; 3. Gastrointestinal reactions: metallic taste, nausea, loss of appetite, indigestion, diarrhea; 4. Kidney reactions: polyuria, nocturia, kidney and urinary tract stones, etc. 5. Temporary myopia may occur, and sulfonamide rash and exfoliative dermatitis may also occur. Rare side effects: 1. Electrolyte disorders: metabolic acidosis, hypokalemia, supplementation of sodium bicarbonate and potassium salts may alleviate symptoms; 2. Hearing loss; 3. The most serious adverse reactions are hematopoietic system disorders: acute hemolytic anemia, granulocytopenia, thrombocytopenia, eosinophilia, aplastic anemia, and renal failure. Long-term use of the drug can aggravate symptoms such as hypokalemia, hyponatremia, electrolyte disorders and metabolic acidosis. The decrease in blood potassium can weaken the intraocular pressure-lowering effect of this product. For patients with kidney stones, this product may induce or aggravate the condition. If renal colic and hematuria occur, the drug should be discontinued immediately.

Hepatic and renal dysfunction leading to hyponatremia, hypokalemia, hyperchloremic acidosis, adrenal failure and adrenocortical insufficiency (Addison's disease), and hepatic coma.

1. When used in combination with adrenocorticotropic hormone, glucocorticoids, especially mineralocorticoids, it can cause severe hypokalemia. When using the drugs in combination, attention should be paid to monitoring the serum potassium concentration and cardiac function. It should also be estimated that long-term simultaneous use increases the risk of hypocalcemia and can cause osteoporosis, because these drugs can increase calcium excretion. 2. When used in combination with amphetamine, anti-M cholinergic drugs, especially atropine and quinidine, the excretion of this product is reduced due to the formation of alkaline urine, which can aggravate or prolong adverse reactions. 3. When used in combination with antidiabetic drugs (such as insulin), it can reduce hypoglycemia reactions, because this product can cause hyperglycemia and glycosuria, so the dosage should be adjusted. 4. When used in combination with phenobarbital, carbamazepine or phenytoin, it can cause an increase in the incidence of osteomalacia. 5. When digitalis glycosides are used in combination with this product, the toxicity of digitalis can be increased and hypokalemia can occur. 6. When used in combination with mannitol or urea, it can increase urine volume while enhancing the effect of reducing intraocular pressure.

Keep away from light and store in sealed container.

0.25g

Jiangsu Changjiang Pharmaceutical Co., Ltd.

• Founded in:

  2002-06-20

• Address:

  No. 28 Hongqi Road, Hede Town, Sheyang County

• Tax NO.:

  91320924742499840X

• Registered Funds:

  66 million yuan

• Website:

  Log in to view

• Email:

  Log in to view